Skip to content
PaperFren

Cognitive aging

Can ML flag high-risk AS+HFpEF after TAVR?

Wang J, Zhu J, Li H, et al. · Journal of medical Internet research · 2025

Open access · cc by · source: Europe PMC

In 326 TAVR patients, an 8-feature SVM reached validation AUC 0.756 for 12-month MACCE, explained with SHAP.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.

Study at a glance

Design
Cohort — Multicenter retrospective TAVR cohort with train/validation ML risk models
N
N=326 · 195 derivation + 131 external validation patients
Population
Older patients with severe aortic stenosis and HFpEF undergoing TAVR
Outcome
12-month major adverse cardiovascular and cerebrovascular events predicted by explainable ML

Structured fields used in claim comparison tables when every cited study has a complete layer.

Inspect source passages

Can ML flag high-risk AS+HFpEF after TAVR?

These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.

326 patients; train n=195; validation n=131.

This multicenter cohort study included 326 patients diagnosed with severe AS and HFpEF who underwent TAVR between January 2017 and December 2023. Patients were allocated to training (n=195) and independent validation (n=131) sets based on hospital affiliation.

SVM validation AUC was 0.756 (95% CI 0.631–0.881).

achieving an area under the curve of 0.756 (95% CI 0.631-0.881) in the independent validation set
Read passages in the original paper

Key findings

SVM performed best (AUC 0.756); features centered on age, NT-proBNP, and metabolic lipid-glucose indices; good calibration/net benefit claimed vs alternatives.

Methodology

Selected features via LASSO+Boruta, trained five ML models on 195 patients, validated on 131 from other hospitals, and interpreted with SHAP.

Limitations

Prospective deployment benefit, or psychology-primary mechanisms (cardiac cohort framed for aging risk markers).

Related papers in this topic

Same topic cluster — not a recommendation engine.